Individualizing Narcolepsy: Using Clinical Evidence and Patient Factors to Improve Diagnosis and Optimize Therapeutic Management

Program Description

Sleep experts Drs. Lynn Marie Trotti, Asim Roy, and Anne Marie Morse offer a comprehensive approach to narcolepsy treatment, embracing recent pharmacological advancements (e.g., pitolisant, solriamfetol, low sodium oxybate [LXB], once nightly sodium oxybate [ON-SXB]). Learners will explore how to tailor individual treatment regimens by moving beyond traditional focuses like cataplexy and excessive daytime sleepiness to address newer concerns such as disrupted nighttime sleep and autonomic dysfunction. Through in-depth discussions, the faculty will cover optimal diagnostic approaches and how to navigate critical decision-making factors (e.g., family planning, dosing preferences, comorbidities). Through this activity, learners will gain valuable insights into managing complex narcolepsy cases.

Target Audience

The target audience for this activity includes sleep specialists, general neurologists and other healthcare professionals involved in the diagnosis and long-term management of patients with sleep disorders.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Identify key clinical characteristics and indicators of narcolepsy type-1 (NT-1) and narcolepsy type-2 (NT-2) to more rapidly and effectively recognize and diagnose these conditions
  • Describe the clinical profiles of and phase 3 data supporting recently approved therapeutic strategies for EDS secondary to narcolepsy with and without cataplexy to discern how and for whom these agents can be effectively and safely prescribed
  • Evaluate the impact of patient considerations (e.g., contraception), situational factors (e.g., prior medication failures), and comorbidities on therapeutic selection for patients with EDS secondary to narcolepsy and customize their regimens to maximize both safety and efficacy
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
03/05/2024
Course expires: 
03/05/2025
Cost:
$0.00
Rating: 
0

   Lynn Marie Trotti, MD, MSc
   Associate Professor of Neurology
   Emory Sleep Center
   Emory University School of Medicine
   Atlanta, GA
 
 

 

   Anne Marie Morse, DO, FAASM
   Associate Professor, Geisinger Commonwealth School of Medicine
   Director, Child Neurology and Pediatric Sleep Medicine Geisinger Medical Center
   Janet Weis Children’s Hospital
   Danville, PA

 

 


   Asim Roy, MD
   Medical Director
   Ohio Sleep Medicine Institute
   Clinical Assistant Professor
   Northeast Ohio Medical University
   Dublin, OH

 

 

This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

image                    image

Joint Accreditation Statement

image

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PHYSICIAN CREDIT
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Disclosure of Relevant Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.

Staff Disclosures

Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

Faculty Disclosures

Dr. Trotti reported no relevant financial relationship.
Dr. Trotti is a member of the Board of Directors of the American Academy of Sleep Medicine.  Any opinions she expresses in this presentation are her own, and do not necessarily reflect those of the AASM or its board.
Dr. Morse reported no relevant financial relationship.
 
Dr. Roy reported the following financial relationships:
  • Grants/Research Support: Harmony, Jazz, Nyxoah, Takeda
  • Speakers Bureau: Harmony, Inspire, Jazz

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Harmony Biosciences and Avadel Pharmaceuticals. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Commercial Support

This activity is supported by educational grants from Harmony Biosciences and Avadel Pharmaceuticals.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period March 15, 2024, through March 15, 2025, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Media

Internet

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.